FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...

Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Meanwhile, drugmakers are expected to raise prices on over 250 medications in the new year; rules for hospital price transparency are updated; and more.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Starting New Year’s Day, drugmakers were set to increase prices on at least 250 brand-name medications, according to data ...

Positive results could help validate Lilly’s bet on Morphic and put the company on track to compete with oral IBD medicines ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...